S&P Futures
4,059.25 +1.75 (+0.04%) Dow Futures
32,912.00 +9.00 (+0.03%) Nasdaq Futures
12,958.75 -6.25 (-0.05%) Russell 2000 Futures
1,783.70 -0.60 (-0.03%) Crude Oil
72.79 -0.18 (-0.25%) Gold
1,961.70 -5.20 (-0.26%)
Odyssey Health, Inc. (ODYY)
Chart Events
Performance Outlook
| Previous Close | 0.0900 |
| Open | 0.0800 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0741 - 0.0891 |
| 52 Week Range | 0.0650 - 0.5600 |
| Volume | |
| Avg. Volume | 130,378 |
| Market Cap | 6.735M |
| Beta (5Y Monthly) | -0.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0440 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- News Direct
Odyssey Health, Inc. Forms Community-Based Partnership with David R. Metcalf Foundation for Military Concussion Research
McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announces a Community-Base...
- GlobeNewswire
Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote
Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote. Chemical warfare using organophosphate nerve agents is a threat worldwide. The risk could not be higher for civilians and military personnel operating in conflict areas like Ukraine. Nerve agent
- GlobeNewswire
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today presents a Company update and recap of its product development programs. The Company has medical products in development which it intends to move forward in their respective clinical programs with the goal of FDA submission and commercialization. “We are extremely pleased with the progress our compan
